

StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees

Osaka, Japan, September 10, 2026 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that fixed details issuance 19th Stock Acquisition Rights (a) of StemRIM (“Stock Option”) to StemRIM employees based on the board of directors' meeting held on September 9, 2026.

19th Stock Acquisition Rights (a) of StemRIM

1. Total number of Stock Option	4,989 units
2. Type and number of shares	498,900 shares of common stock, 100 shares per unit
3. Exercise price	24,500 yen per unit, 245 yen per shares
4. Persons to whom stock acquisition rights are to be allocated, their number, and the number of stock acquisition rights to be allotted	Employees of StemRIM 47

(Reference)StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees, Dated September 9, 2026

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH),

systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)